I think the same...
Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
Celldex Therapeutics - Investors - News Release
Its near 52 week low and has great upward potential....
Your thought?



LinkBack URL
About LinkBacks
Reply With Quote
